SILO PHARMA INC (SILO) Stock News
NASDAQ:SILO - Nasdaq - US82711P2011 - Common Stock - Currency: USD
SILO Latest News, Press Relases and Analysis
Get insights into the top gainers and losers of Monday's pre-market session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
These stocks are moving in today's pre-market session
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Mentions: HOTH
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the formation of a strategic joint venture to...
Mentions: HOTH
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Strategic decision positions Company to diversify treasury holdings with a long-term digital store of value
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Strategic decision positions Company to diversify treasury holdings with a long-term digital store of value ...
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
Study is expected to deliver final device data and documentation needed for planned FDA IND submission
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
Study is expected to deliver final device data and documentation needed for planned FDA IND submission...
Silo Pharma Announces Closing of $2 Million Public Offering
Silo Pharma Announces Closing of $2 Million Public Offering
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
Silo Pharma Announces Pricing of $2 Million Public Offering
Silo Pharma Announces Pricing of $2 Million Public Offering
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment
The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market...
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....